Friday, March 27, 2026 For Patients CME Credits Newsletters
Subscribe

Neurology

4 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Psoriasis Linked to 24% Increased Stroke Risk, Especially in Severe Cases
Meta-analysis of 18 studies shows psoriasis patients have a 24% higher stroke risk (HR 1.24, 95% CI: 1.15-1.35, P<.05), with severe cases at greater risk.
Researchers studied the link between psoriasis and stroke risk. They found that people with psoriasis, especially those with severe cases, have a higher chance of having a stroke.…
Tailored Home Intervention Reduces Falls by 33% in Stroke Patients
A randomized trial found a 33% reduction in fall rates among stroke patients receiving a tailored home intervention (IRR 0.67, 95% CI 0.48-0.94; P=0.02).
Researchers studied a special home program to help stroke survivors avoid falls. They found that this program significantly reduced the number of falls among participants.…
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years
In a 5-year extension of the OPTIMUM study, ponesimod 20 mg maintained a lower ARR (0.143) compared to teriflunomide switchers (0.184). Serious TEAEs occurred in 12.9% of participants, with no new saf…
Researchers studied the long-term effects of ponesimod in patients with relapsing multiple sclerosis. They found that most patients experienced some side effects, but ponesimod was effective in reduci…
rTMS and TBS Improve Unilateral Spatial Neglect Post-Stroke: Meta-Analysis of 425 Patients
Meta-analysis of 17 studies (n=425) shows rTMS and TBS significantly reduce neglect severity in USN post-stroke, with rTMS improving LBT (SMD -1.82, P<0.00001) and SCT (SMD -1.59, P<0.00001).
Researchers studied how different brain stimulation methods can help stroke patients with attention issues. They found that some methods were more effective than others in improving daily activities.…
CT.gov · Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Childr… CT.gov · Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients CT.gov · Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma CT.gov · Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD CT.gov · Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria CT.gov · Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary O…